Sierra Oncologylaunched theMOMENTUMclinical trial for patients with myelofibrosis in November 2019. The randomized, double-blind, global phase 3 trial is designed to confirm the efficacy ofmomelotinibon myelofibrosis symptoms, transfusion independence, and splenomegaly, as compared to danazol. Momelotinib had previously been under Gilead before being sold to Sierra in 2018. The trial is targeting enrollment of 180 myelofibrosis patients who are symptomatic, anemic and have been treated previously with a JAK inhibitor.

According to the Chief Investigator Dr. Verstovsek, “Momelotinib could become a suitable alternative for many patients previously treated with a JAK inhibitor due to its ability to positively address all three hallmarks of myelofibrosis – symptoms, anemia and an enlarged spleen. Critically, momelotinib has consistently demonstrated positive anemia benefits in its prior clinical trials. This anemia benefit is biologically-driven, via potent inhibition of the ACVR1/hepcidin axis, a mechanism that is unique in the JAK inhibitor class.”

The MOMENTUM clinical trial will be available to myelofibrosis patients all over the world. The following list of countries will be participating in the study with active sites. Those countries include Australia, Austria, Belgium, Bulgaria, Canada, Czech Republic, Denmark, France, Germany, Hungary, Israel, Italy, New Zealand, Poland, Romania, Singapore, South Korea, Spain, Sweden, Taiwan, United Kingdom, and the United States.

Clickhere to read more about the MOMENTUM study on clinicaltrials.gov.